While You Were Out: News In Brief
Updates from the holiday season include a Phase III failure for Pfizer's MRSA vaccine, AbbVie's submission of upadacitinib for rheumatoid arthritis and several year-end US approvals and FDA actions.
You may also be interested in...
Sunovion Plans September Launch For Parkinson’s 'Off' Episode Drug Kynmobi
Kynmobi is an important approval for parent company Sumitomo Dainippon ahead of the loss of exclusivity for Latuda. Sunovion hopes to launch after COVID-19 social distancing requirements ease.
Keeping Track: Industry Beefs Up 2020 Review Pipeline With Submissions Galore
The latest drug development news and highlights from our US FDA Performance Tracker.
Acorda Restructures, Cuts Jobs By 25% With No Deals, Big Debt On The Horizon
Acorda is cutting jobs to save $21m annually and otherwise lowering expenses for a total of $60m in reduced costs in 2020 to focus on marketing Inbrija, but looming overhead is $345m in debt due in 2021. Meanwhile, ex-US partners and company buyers appear nowhere in sight.